Boston, Massachusetts, United States
Temporary postdoctoral research position to finalize revision of publication - Evaluated the preclinical efficacy of therapeutic agents through extensive in vitro tissue culture, in vivo patient-derived mouse xenograft, and organoid models. Elucidated the molecular mechanism of action through transcriptomic and epigenomic approaches (RNA-seq, ChIP-seq, CUT&RUN), as well as RNAi and CRISPR/Cas9 technologies inform the discovery of functional biomarkers
- Conducted scientific diligence on biotechnology startups from early to late-stage funding; engaged in pitch calls and consultations with KOLs to evaluate potential investment opportunities - Contributed to deal sourcing through therapeutic focus area research projects in neoantigen directed immunotherapies, analysis of competitive landscapes, and broader biotech sectors - Created and presented a guide on evaluating preclinical oncology data to the biotech investment team to establish a standardized framework for conducting due diligence on clinical oncology companies
Thesis: Identified and investigated combination therapies for metastatic RAS-driven colorectal cancers through preclinical drug studies, and elucidated the molecular mechanisms to inform the development of treatment strategies Extensive experience with in vivo preclinical models, including patient derived xenografts (PDXs), in vitro tissue culture, and patient-derived and intestinal organoid models. Utilized high throughput assays to evaluate efficacy of therapeutic agents, and transcriptomic and epigenomic approaches (RNA-seq, ChIP-seq, CUT&RUN) to identify novel target genes that underlie the mechanism of action Awarded with F31 NRSA fellowship from the NIH and National Cancer Institute
Utilized high throughput analytical chemistry techniques to identify novel small molecules and compounds that regulate nuclear receptor signaling in C. elegans development